Protagonist Therapeutics (PTGX) Return on Capital Employed (2016 - 2026)
Protagonist Therapeutics (PTGX) posted Return on Capital Employed of 21.98% for Q1 2026, up 11.12% sequentially from 24.73% in Q4 2025, and down 2582.0% YoY from 0.89% in Q1 2025.
Protagonist Therapeutics (PTGX) Return on Capital Employed (2016 - 2026) Analysis & Trends
Protagonist Therapeutics has reported Return on Capital Employed for 11 years, with the latest figure at 21.98% in Q1 2026.
- Quarterly Return on Capital Employed fell 2582.0% year-over-year to 21.98% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 21.98% (down 2582.0% YoY) and the FY2025 annual result came in at 23.92%, down 7410.0% from the prior year.
- Return on Capital Employed grew to 21.98% in Q1 2026 per PTGX's latest filing, from 24.73% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 40.33% in Q4 2024 and troughed at 66.29% in Q1 2023.
- A 5-year average of 18.18% and a median of 24.73% in 2025 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed jumped 9906 bps in 2024, then slumped 6506 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 56.17% in 2022, then jumped by 48 bps to 29.02% in 2023, then soared by 239 bps to 40.33% in 2024, then plunged by 161 bps to 24.73% in 2025, then rose by 11 bps to 21.98% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 21.98%, 24.73%, and 2.86% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Protagonist Therapeutics | 10.03 Bn | 10.03 Bn | - | 7.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.73% |
| Mar 31, 2026 | -21.98% |
| Dec 31, 2025 | -24.73% |
| Sep 30, 2025 | 2.86% |
| Jun 30, 2025 | 3.45% |
| Mar 31, 2025 | 3.84% |
| Dec 31, 2024 | 40.33% |
| Sep 30, 2024 | 26.41% |
| Jun 30, 2024 | 26.23% |
| Mar 31, 2024 | 32.77% |
| Dec 31, 2023 | -29.02% |
| Sep 30, 2023 | -51.52% |
| Jun 30, 2023 | -58.00% |
| Mar 31, 2023 | -66.29% |
| Dec 31, 2022 | -56.17% |
| Sep 30, 2022 | -50.80% |
| Jun 30, 2022 | -46.14% |
| Mar 31, 2022 | -40.37% |
| Dec 31, 2021 | -39.77% |
| Sep 30, 2021 | -30.80% |